SynthesisEndocrine2019
Effectiveness and safety of pegvisomant: a systematic review and meta-analysis of observational longitudinal studies.
Synthesis in Endocrine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 49 citations in OpenAlex.
- Combined therapy of somatostatin analogues with pegvisomant for the treatment of acromegaly: a meta-analysis of prospective studies.BMC endocrine disorders · 2020Pooled it
- Current treatment landscape of acromegaly.The Journal of clinical endocrinology and metabolism · 2026Review
- Long-term safety and efficacy of pegvisomant monotherapy for acromegaly: final data from the full ACROSTUDY cohort.Pituitary · 2026Article
- Pegvisomant in managing comorbidities of acromegaly: a review.Reviews in endocrine & metabolic disorders · 2026Review
- Cost-effectiveness of pasireotide as second-line therapy for adult acromegaly patients from the perspective of the Brazilian Unified Health System.Frontiers in endocrinology · 2026Article
- Consensus on acromegaly therapeutic outcomes: an update.Nature reviews. Endocrinology · 2025Review
- Acromegaly: diagnostic challenges and individualized treatment.Expert review of endocrinology & metabolism · 2025Review
- Real-Life Data on the Safety of Pasireotide in Acromegaly: Insights from EudraVigilance.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Medical treatment of functional pituitary adenomas, trials and tribulations.Journal of neuro-oncology · 2024Review
- Control of acromegaly in more than 90% of patients after 10 years of pegvisomant therapy: an European referral centre real-life experience.Journal of endocrinological investigation · 2023Article
- Development of Pharmaceutical Nanomedicines: From the Bench to the Market.Pharmaceutics · 2022Review
- Acromegaly: Clinical Care in Central and Eastern Europe, Israel, and Kazakhstan.Frontiers in endocrinology · 2022Review
- Treatment of acromegaly by rosiglitazone via upregulating 15-PGDH in both pituitary adenoma and liver.iScience · 2021Article
- More than a decade of real-world experience of pegvisomant for acromegaly: ACROSTUDY.European journal of endocrinology · 2021Article
- A Pituitary Society update to acromegaly management guidelines.Pituitary · 2021Review
- Cost-Utility of Acromegaly Pharmacological Treatments in a French Context.Frontiers in endocrinology · 2021Article
- Multidisciplinary management of acromegaly: A consensus.Reviews in endocrine & metabolic disorders · 2020Review
- [Pituitary adenomas].Der Nervenarzt · 2019Review
- Nanopharmaceuticals and nanomedicines currently on the market: challenges and opportunities.Nanomedicine (London, England) · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeAcromegaly is a rare disease that often requires drug treatment to achieve control, with pegvisomant being one of the most widely used therapies. In the present paper, we aimed to obtain evidence regarding the effectiveness and safety of pegvisomant by reviewing real-world observational longitudinal studies.
methodsA systematic review was performed with a meta-analysis of event rates (95% confidence interval (CI)) using a random effects model. Sensitivity and subgroup analyses were performed (comprehensive meta-analysis 2.0). The systematic review was performed in accordance to preferred reporting items for systematic reviews and meta-analyses, meta-analysis of observational studies in epidemiology, and Cochrane recommendations (PROSPERO register CRD 42017059880). PubMed, Scopus, Web of Science, and SciELO were used to search for literature. Observational studies in patients using pegvisomant for the treatment of acromegaly were included.
resultsInitially, 552 papers were retrieved from the databases; and 31 articles were included in the qualitative analysis and 14 in the quantitative analysis. Eight primary meta-analyses were performed. The overall rate of patients with disease control was of 60.9% (51.8-69.3%; 95% CI). When considering patients under monotherapy, the control rate was 71.7% (64.0-78.4%; 95% CI). Tumor growth was estimated in 7.3% (4.7-11.1%; 95% CI) and elevation of transaminases in 3.0% (1.7-5.2%; 95% CI).
conclusionsThe real-world data showed that the effectiveness of pegvisomant is not as high as reported in interventional studies. Acromegaly appears to be better controlled when pegvisomant is used as a monotherapy. No serious adverse events were associated with the use of pegvisomant; however, given the high cost of this drug, further studies are required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.